EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Bisdemethoxycurcumin attenuates myocardial fibrosis in heart failure with preserved ejection fraction by targeting TGFBR1 and oxidative stress

Rong Xu, Guihua Cao, Liming Hou, Wei Fu, Chenting Bi, Xu Li, Xiaoming Wang

Computational and Structural Biotechnology Journal · 2026-01 · 31 · 422-435

DOI: 10.1016/j.csbj.2026.01.009 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Computational and Structural Biotechnology Journal, online erschienen am 14.01.2026. Verfasst von Rong Xu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Geriatrics, Xijing Hospital, The Airforce Military Medical University, Xi'an, Shaanxi 710032, China. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shaanxi Province Key Research and Development Projects.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bisdemethoxycurcumin (BDMC), a natural derivative of curcumin with improved solubility and stability, has shown potential cardioprotective properties. This study investigated the efficacy and underlying mechanisms of BDMC in heart failure with preserved ejection fraction (HFpEF) using both in vivo and in vitro models. The HFpEF mouse model was established using a high-fat diet and L-NAME. BDMC treatment improved cardiac function, attenuated myocardial fibrosis, and exhibited antioxidant effects. Mechanistically, integrated network pharmacology and proteomics identified TGFBR1 as a potential target. BDMC inhibited cardiac fibroblast activation by suppressing TGFBR1 expression and SMAD2/3 phosphorylation. Molecular docking and dynamics simulations confirmed stable binding between BDMC and TGFBR1. These findings demonstrate that BDMC mitigates myocardial fibrosis in HFpEF, primarily by competitively inhibiting the binding of TGF-β and TGFBR1, achieving the effect of inhibiting cardiac fibroblast activation.

Schlagwörter

Stichwörter der Autor:innen

BisdemethoxycurcuminExperimental validationHeart failure with preserved ejection fractionMolecular dockingNetwork pharmacology

Autor:innen und Institutionen

  • Department of Geriatrics, Xijing Hospital, The Airforce Military Medical University, Xi'an, Shaanxi 710032, China.

Förderung

  • Shaanxi Province Key Research and Development Projects

Zitieren

APA

Xu, R., Cao, G., Hou, L., Fu, W., Bi, C., Li, X., & Wang, X. (2026). Bisdemethoxycurcumin attenuates myocardial fibrosis in heart failure with preserved ejection fraction by targeting TGFBR1 and oxidative stress. Computational and Structural Biotechnology Journal, 31, 422-435. https://doi.org/10.1016/j.csbj.2026.01.009

Vancouver

Xu R, Cao G, Hou L, Fu W, Bi C, Li X, et al. Bisdemethoxycurcumin attenuates myocardial fibrosis in heart failure with preserved ejection fraction by targeting TGFBR1 and oxidative stress. Computational and Structural Biotechnology Journal. 2026;31:422-435. doi:10.1016/j.csbj.2026.01.009

BibTeX
@article{Xu2026,
  author = {Xu, Rong and Cao, Guihua and Hou, Liming and Fu, Wei and Bi, Chenting and Li, Xu and Wang, Xiaoming},
  title = {Bisdemethoxycurcumin attenuates myocardial fibrosis in heart failure with preserved ejection fraction by targeting TGFBR1 and oxidative stress},
  journal = {Computational and Structural Biotechnology Journal},
  year = {2026},
  volume = {31},
  pages = {422--435},
  doi = {10.1016/j.csbj.2026.01.009}
}
Kostenlos starten →